Toggle light / dark theme

Still calling 2025 for the debut of a robotic set of human level hands.


Although robotic devices are used in everything from assembly lines to medicine, engineers have a hard time accounting for the friction that occurs when those robots grip objects – particularly in wet environments. Researchers have now discovered a new law of physics that accounts for this type of friction, which should advance a wide range of robotic technologies.

“Our work here opens the door to creating more reliable and functional haptic and robotic devices in applications such as telesurgery and manufacturing,” says Lilian Hsiao, an assistant professor of chemical and biomolecular engineering at North Carolina State University and corresponding author of a paper on the work.

At issue is something called elastohydrodynamic lubrication (EHL) friction, which is the friction that occurs when two solid surfaces come into contact with a thin layer of fluid between them. This would include the friction that occurs when you rub your fingertips together, with the fluid being the thin layer of naturally occurring oil on your skin. But it could also apply to a robotic claw lifting an object that has been coated with oil, or to a surgical device that is being used inside the human body.

The project is a part of a much wider effort to bring artificial intelligence into the operating room. Using many of the same technologies that underpin self-driving cars, autonomous drones and warehouse robots, researchers are working to automate surgical robots too. These methods are still a long way from everyday use, but progress is accelerating.


Real scalpels, artificial intelligence — what could go wrong?

A bold project to read the complete genetic sequences of every known vertebrate species reaches its first milestone by publishing new methods and the first 25 high-quality genomes.

It’s one of the most audacious projects in biology today – reading the entire genome of every bird, mammal, lizard, fish, and all other creatures with backbones.

And now comes the first major payoff from the Vertebrate Genomes Project (VGP): near complete, high-quality genomes of 25 species, Howard Hughes Medical Institute (HHMI) Investigator Erich Jarvis with scores of coauthors report April 28, 2021, in the journal Nature. These species include the greater horseshoe bat, the Canada lynx, the platypus, and the kākāpō parrot – one of the first high-quality genomes of an endangered vertebrate species.

An acquired mutation in the cancer-causing gene PIK3CA can make blood vessel malformations in the brain worse, possibly explaining why these abnormal clusters sometimes rapidly increase in size and cause stroke or seizures, shows new research.


Research from the University of Pennsylvania and Duke University shows an acquired mutation in the cancer-causing gene PIK3CA can trigger uncontrolled growth in cerebral cavernous malformations often leading to strokes or seizures in those affected.

After a mechanic from the United Kingdom lost his penis, medical innovators fashioned him a replacement out of his existing tissue — and it now rests on his left forearm.

45-year-old Malcolm MacDonald suffered from a perineum infection which led to a severe case of sepsis in 2014, which spread to his extremities, turning his fingers and toes black. Then it began to also affect his genitalia. “When I saw my penis go black I was beside myself,” MacDonald told The Sun. “It was like a horror film…I knew deep down it was gone and I was going to lose it. Then one day it just dropped off on to the floor.”

For two years afterwards, MacDonald says his life “fell apart”, until he was referred to Professor David Ralph, a urologist at University College London Hospital who specializes in penile reconstruction surgery.

While the CRISPR-Cas9 gene editing system has become the poster child for innovation in synthetic biology, it has some major limitations. CRISPR-Cas9 can be programmed to find and cut specific pieces of DNA, but editing the DNA to create desired mutations requires tricking the cell into using a new piece of DNA to repair the break. This bait-and-switch can be complicated to orchestrate, and can even be toxic to cells because Cas9 often cuts unintended, off-target sites as well.

Alternative gene editing techniques called recombineering instead perform this bait-and-switch by introducing an alternate piece of DNA while a cell is replicating its genome, efficiently creating without breaking DNA. These methods are simple enough that they can be used in many cells at once to create complex pools of mutations for researchers to study. Figuring out what the effects of those mutations are, however, requires that each mutant be isolated, sequenced, and characterized: a time-consuming and impractical task.

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) have created a new gene editing tool called Retron Library Recombineering (RLR) that makes this task easier. RLR generates up to millions of mutations simultaneously, and “barcodes” mutant cells so that the entire pool can be screened at once, enabling massive amounts of data to be easily generated and analyzed. The achievement, which has been accomplished in , is described in a recent paper in PNAS.

Artificial womb technology for extremely preterm infants — jasmijn kok, juno perinatal healthcare.


Every year, 800000 babies are born extremely preterm (defined as less than 28 weeks of age) worldwide. These infants are usually transferred to an air-based neonatal intensive care unit to support their heart and lung development. Exposure to air, however, leads to many complications, because the lungs are not fully developed yet.

An artificial uterus, or artificial womb, is a device that would allow for extra-corporeal pregnancy, by supporting the growth of a fetus outside the body of an organism that would normally carry the fetus to term.

Juno Perinatal Healthcare (https://www.junoperinatalhealthcare.com/) is a fascinating Dutch neonatal healthcare start-up which has a mission of developing a novel, alternative environment, similar to the mother’s womb, where extremely premature babies could be transferred, where the lungs remain filled with fluid and the umbilical cord will be attached to an artificial placenta to improve their organ development and ease the transition to newborn life.

Juno Perinatal Healthcare is a companion project to a interdisciplinary consortium known as the Perinatal Life Support (PLS) Project (https://perinatallifesupport.eu/), a consortium of three European universities, Aachen, Milan and Eindhoven, to establish the first ex-vivo fetal maturation system for clinical use.

Mitochondria are the energy suppliers of our body cells. These tiny cell components have their own genetic material, which triggers an inflammatory response when released into the interior of the cell. The reasons for the release are not yet known, but some cardiac and neurodegenerative diseases as well as the aging process are linked to the mitochondrial genome. Researchers at the Max Planck Institute for Biology of Aging and the CECAD Cluster of Excellence in Aging research have investigated the reasons for the release of mitochondrial genetic material and found a direct link to cellular metabolism: when the cell’s DNA building blocks are in short supply, mitochondria release their genetic material and trigger inflammation. The researchers hope to find new therapeutic approaches by influencing this metabolic pathway.

Our body needs energy—for every metabolic process, every movement and for breathing. This energy is produced in tiny components of our body , the so-called mitochondria. Unlike other cell components, mitochondria have their own genetic material, mitochondrial DNA. However, in certain situations, mitochondria release their DNA into the interior of the cell, causing a reaction from the cell’s own immune system and being associated with various diseases as well as the aging process. The reasons for the release of mitochondrial DNA are not yet known.

But the biotech industry has argued that much of gene-editing simply accelerates processes that occur naturally, and that GMO-style regulation would shackle efforts to develop sustainable crops or advance research into human disease.


The European Commission launched a review of EU rules on genetically modified organisms (GMOs) on Thursday, opening the door to a possible loosening of restrictions for plants resulting from gene-editing technology.

Prompted by a 2018 ruling from the European Union’s top court that techniques to alter the genome of an organism should be governed by existing EU rules on GMOs, the Commission concluded that its 2001 legislation was “not fit for purpose”.

Gene-editing technology targets specific genes within an organism to promote certain characteristics or curb others, while genetic modification involves transferring a gene from one kind of organism to another.

Novel bio-sensing technologies to reduce food waste and optimize supply chains — a US$1 trillion need — katherine sizov — founder, strella biotechnology.


An estimated 40% of all global produce is wasted due to spoilage that occurs before it ever reaches consumers’ grocery bags. And this loss, not only represents loss due to quality or ripeness standards that consumers desire, but also a significant impact on global emissions and fresh water supplies that it took to produce and transport that produce, representing a combined figure of US$1 Trillion annually.

Katherine Sizov is the Founder of Strella Biotechnology (https://www.strellabiotech.com/), a company that builds novel bio-sensing platforms that can predict the ripeness of fruit and ultimately use this information to optimize supply chains by reducing food waste and increasing produce margins.

Strella won the 2019 President’s Innovation Prize (PIP) award from University of Pennsylvania, the grand prize at the Arizona State University Innovation Open, and the Venture Award at O3 World’s 1682 conference, and is recently is coming off of a US$3.3 million seed round with some very prominent institutional investors, including Marc Cuban Companies, Yamaha Motor Ventures & Laboratory Silicon Valley, and Catapult Ventures.

Katherine studied Molecular Biology and Chemistry, as well as Engineering Entrepreneurship, at the University of Pennsylvania.